Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors
- Author
- PASCHKA, P1 ; MÜLLER, M. C1 ; GSCHAIDMEIER, H3 ; HEHLMANN, R1 ; HOCHHAUS, A1 ; MERX, K1 ; KREIL, S1 ; SCHOCH, C2 ; LAHAYE, T1 ; WEISSER, A1 ; PETZOLD, A1 ; KÖNIG, H1 ; BERGER, U1
[1] III, Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universitat Heidelberg, Mannheim, Germany
[2] Medizinische Klinik 3, Klinikum Grosshadern der Universität, München, Germany
[3] Novartis Pharma GmbH, Nürnberg, Germany - Source
Leukemia. 2003, Vol 17, Num 9, pp 1687-1694, 8 p ; ref : 42 ref
- CODEN
- LEUKED
- ISSN
- 0887-6924
- Scientific domain
- Medical oncology; Hematology
- Publisher
- Nature Publishing, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- FISH chronic myelogenous leukemia imatinib minimal residual disease molecular cytogenetics quantitative RT-PCR
- Keyword (fr)
- Analyse quantitative Chimiothérapie Chronique Cytogénétique Homme Hybridation in situ fluorescence Imatinib Immunothérapie Inhibiteur enzyme Interféron alpha Leucémie myéloïde Maladie résiduelle imperceptible Protein-tyrosine kinase Réaction chaîne polymérase RT Surveillance biologique Traitement Enzyme Hémopathie maligne Myéloprolifératif syndrome Transferases
- Keyword (en)
- Quantitative analysis Chemotherapy Chronic Cytogenetics Human Fluorescence in situ hybridization Imatinib Immunotherapy Enzyme inhibitor Alpha interferon Chronic myelocytic leukemia Minimal residual disease Protein-tyrosine kinase Reverse transcription polymerase chain reaction Biological monitoring Treatment Enzyme Malignant hemopathy Myeloproliferative syndrome Transferases
- Keyword (es)
- Análisis cuantitativo Quimioterapia Crónico Citogenética Hombre Hibridación in situ fluorescencia Imatinib Inmunoterapia Inhibidor enzima Interferón alfa Leucemia mieloidea Enfermedad residual imperceptible Protein-tyrosine kinase Reacción cadena polimerasa transcripción inversa Vigilancia biológica Tratamiento Enzima Hemopatía maligna Mieloproliferativo síndrome Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15160665
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.leu.2403033 
https://dx.doi.org/10.1038/sj.leu.2403033
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1687\";s:8:\"\u0000*\u0000epage\";s:4:\"1694\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PASCHKA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:13:\"M\u00dcLLER, M. C\";i:1;s:15:\"GSCHAIDMEIER, H\";i:2;s:11:\"HEHLMANN, R\";i:3;s:11:\"HOCHHAUS, A\";i:4;s:7:\"MERX, K\";i:5;s:8:\"KREIL, S\";i:6;s:9:\"SCHOCH, C\";i:7;s:9:\"LAHAYE, T\";i:8;s:10:\"WEISSER, A\";i:9;s:10:\"PETZOLD, A\";i:10;s:9:\"K\u00d6NIG, H\";i:11;s:9:\"BERGER, U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1687\";s:8:\"\u0000*\u0000epage\";s:4:\"1694\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PASCHKA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:13:\"M\u00dcLLER, M. C\";i:1;s:15:\"GSCHAIDMEIER, H\";i:2;s:11:\"HEHLMANN, R\";i:3;s:11:\"HOCHHAUS, A\";i:4;s:7:\"MERX, K\";i:5;s:8:\"KREIL, S\";i:6;s:9:\"SCHOCH, C\";i:7;s:9:\"LAHAYE, T\";i:8;s:10:\"WEISSER, A\";i:9;s:10:\"PETZOLD, A\";i:10;s:9:\"K\u00d6NIG, H\";i:11;s:9:\"BERGER, U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1687\";s:8:\"\u0000*\u0000epage\";s:4:\"1694\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PASCHKA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:13:\"M\u00dcLLER, M. C\";i:1;s:15:\"GSCHAIDMEIER, H\";i:2;s:11:\"HEHLMANN, R\";i:3;s:11:\"HOCHHAUS, A\";i:4;s:7:\"MERX, K\";i:5;s:8:\"KREIL, S\";i:6;s:9:\"SCHOCH, C\";i:7;s:9:\"LAHAYE, T\";i:8;s:10:\"WEISSER, A\";i:9;s:10:\"PETZOLD, A\";i:10;s:9:\"K\u00d6NIG, H\";i:11;s:9:\"BERGER, U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1687\";s:8:\"\u0000*\u0000epage\";s:4:\"1694\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PASCHKA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:13:\"M\u00dcLLER, M. C\";i:1;s:15:\"GSCHAIDMEIER, H\";i:2;s:11:\"HEHLMANN, R\";i:3;s:11:\"HOCHHAUS, A\";i:4;s:7:\"MERX, K\";i:5;s:8:\"KREIL, S\";i:6;s:9:\"SCHOCH, C\";i:7;s:9:\"LAHAYE, T\";i:8;s:10:\"WEISSER, A\";i:9;s:10:\"PETZOLD, A\";i:10;s:9:\"K\u00d6NIG, H\";i:11;s:9:\"BERGER, U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:22:\"10.1038\/sj.leu.2403033\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:9:\"\u0000*\u0000jtitle\";s:8:\"Leukemia\";s:9:\"\u0000*\u0000stitle\";s:8:\"Leukemia\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"17\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:4:\"1687\";s:8:\"\u0000*\u0000epage\";s:4:\"1694\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0887-6924\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"PASCHKA\";s:10:\"\u0000*\u0000aufirst\";s:1:\"P\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:13:\"M\u00dcLLER, M. C\";i:1;s:15:\"GSCHAIDMEIER, H\";i:2;s:11:\"HEHLMANN, R\";i:3;s:11:\"HOCHHAUS, A\";i:4;s:7:\"MERX, K\";i:5;s:8:\"KREIL, S\";i:6;s:9:\"SCHOCH, C\";i:7;s:9:\"LAHAYE, T\";i:8;s:10:\"WEISSER, A\";i:9;s:10:\"PETZOLD, A\";i:10;s:9:\"K\u00d6NIG, H\";i:11;s:9:\"BERGER, U\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LEUKED\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:247:\"Molecular monitoring of response to imatinib (Glivec\u00ae) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitors\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
